CQDM announces funding for three cancer research projects, supported by the Québec government grant. These projects aim to enhance cancer treatment efficacy and reduce side effects. They include Theratechnologies’ platform for colorectal cancer, Saydi Biotech’s MDM2 inhibitor for various cancers, and Roche Canada’s use of circulating tumor DNA for monitoring DLBCL patients. Dr. Ramy Saleh, along with other collaborators, plays a crucial role in Saydi Biotech’s project, emphasizing Québec’s leadership in innovative cancer research.
This group has been created by SaRC-Q to offer a space for sharing, support, and mutual assistance to all those living with GIST (Gastrointestinal Stromal Tumor) in Quebec and Canada. Our goal is to create a supportive and caring community where everyone feels supported and understood. Together, we can help each other overcome the challenges related to GIST and find resources to improve our quality of life. SaRC-Q will be sharing advancements in GIST treatments and insights about this sarcoma, as well as scientific and medical data.
Trials involving Tenosynovial Giant Cell Tumor (TGCT) in Canada now welcome participants from all regions across the country. If you would like to participate in these clinical trials, lodging and transportation are offered to facilitate the participation of eligible individuals. This assistance aims to ensure that geographical distance does not pose a barrier for patients interested in contributing to TGCT research. Prospective participants are encouraged to contact the trial coordinators or investigators to inquire about specific details regarding lodging and transportation arrangements for the particular trial they are interested in.
Montreal, January 26, 2024 – Driven by an extraordinary spirit, the Harding sisters, Cassandra and Katelyn, have faced the same rare cancer—Osteosarcoma—within months of each other. This rare form of cancer, also battled by the iconic Terry Fox, has become a testament to the strength and courage inspired by SaRC-Q co-founder Dr. Ramy Saleh.
Katelyn, a 19-year-old athlete with a passion for rugby and ringette, initially attributed her pain and numbness to sports injuries. However, an X-ray revealed a harsh reality—she, too, was diagnosed with Osteosarcoma, following in the footsteps of her sister Cassandra, who had completed her own treatments six months prior.
Both sisters, tragically losing their mother to cancer, prompted Dr. Saleh and the medical team to investigate a potential genetic link. Tests revealed the presence of the P53 genetic variant in both sisters, predisposing them to a higher risk of developing multiple cancers.
Dr. Ahmed Aoude, a spine and orthopedic oncology surgeon at MUHC, described Katelyn’s surgery as “one of the biggest surgeries in modern medicine.” Despite the complexity and duration of the procedure, the sisters, who have shared their journey on social media, continue to inspire other young patients.
Cassandra is now in remission, while Katelyn, halfway through chemotherapy, undergoes rehabilitation to regain her ability to walk. The Harding family, supported by the Montreal’s MUHC medical staff, remains a beacon of hope and strength in the face of adversity.
To follow their inspiring journey guided by SaRC-Q co-founder Dr. Ramy Saleh, stay connected with us on social media and visit our website for updates on sarcoma research and patient stories.
Source: Pamela Pagano, CityNews
In a groundbreaking study, researchers led by Vanessa Di Lalla at McGill University have conducted a comprehensive review of Radiation-Induced Sarcomas (RISs) of the breast, offering valuable insights into a rare yet critical aspect of cancer treatment.
The findings, spanning a 20-year period, shed light on the incidence, risk factors, management, and outcomes of RISs, contributing significantly to the understanding of these complex malignancies.
Radiation-induced sarcomas (RISs) are a rare but serious consequence of radiotherapy, representing histologically proven sarcomas within or around previously irradiated sites. The study, conducted at McGill University Health Centre, focused on 19 patients meeting Cahan’s criteria for RISs between 2000 and 2020. The median age at RIS diagnosis was 72 years, with a median latency period of 112 months. All patients underwent surgery, and some received additional systemic therapy or reirradiation as salvage treatment.
At a median follow-up of 31 months, the study revealed that despite aggressive treatment, a significant proportion of patients experienced local recurrence, emphasizing the challenges in managing RISs. However, the overall survival outcomes at two years were encouraging, with a disease-specific survival of 88.9%.
The research underscores the need for specialized, multidisciplinary management of breast RISs, particularly in high-volume centers where expertise is readily available. While the study provides valuable insights, the researchers advocate for further investigations, emphasizing the rarity of RISs and the difficulty in drawing definitive conclusions on risk factors.
We are thrilled to announce the initiation of two groundbreaking clinical trials, marking significant strides in the field of sarcoma research. These trials, Abbisko Pimicotimib and PEAK, hold promise in advancing treatment options for patients facing GIST and TGCT challenges.
Abbisko Pimicotimib Trial: Embarking on a phase III journey, this trial is actively recruiting patients with inoperable TGCT (formerly known as PVNS). The study explores the efficacy of pimicotinib, a novel oral TKI, compared to a placebo, with permitted crossover. This represents a crucial step towards addressing the unique challenges posed by inoperable TGCT.
PEAK Trial: A phase III trial open for enrollment, PEAK focuses on patients with advanced GIST who are progressing or intolerant to imatinib. The trial investigates the combination of sunitinib and bezuclastinib versus sunitinib alone, offering a potential paradigm shift in the management of GIST cases.
We invite all eligible patients to consider participation, and healthcare professionals to reach out for patient enrollment. These trials signify our commitment to advancing sarcoma care, and we look forward to the impactful insights they will undoubtedly yield. Stay tuned for updates as we push the boundaries of sarcoma research.